NASDAQ:ADXS

Advaxis - ADXS Stock Forecast, Price & News

$3.38

-0.01 (-0.29%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.38
▼
$3.78
50-Day Range: N/A
52-Week Range: $1.02
▼
$51.60

Volume: 1,496 shs
Average Volume: 6,817 shs
Market Capitalization: $6.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Advaxis

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Advaxis in a research note on Wednesday. They issued a "sell" rating for the company.

Advaxis Stock Performance

Shares of NASDAQ:ADXS opened at $3.39 on Friday. Advaxis has a 1-year low of $1.02 and a 1-year high of $51.60.

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

ADXS Stock News Headlines

August 4, 2022 | americanbankingnews.com

Advaxis (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Advaxis and its competitors with MarketBeat's FREE daily newsletter.

ADXS Company Calendar

Today: 8/12/2022
Fiscal Year End: 10/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADXS
CUSIP: N/A
CIK: 1100397
Web: www.advaxis.com
Phone: 609 452 9813
Fax: 609-452-9818
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($6.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,860,000.00
Net Margins: N/A
Pretax Margin: -2,296.60%
Return on Equity: -39.23%
Return on Assets: -33.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.44
Quick Ratio: 14.44

Sales & Book Value

Annual Sales: $3.24 million
Price / Sales: 1.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $21.36 per share
Price / Book: 0.16

Miscellaneous

Outstanding Shares: 1,816,000
Free Float: 1,811,000
Market Cap: $6.14 million
Optionable: Not Optionable
Beta: 2.22

Key Executives

Mr. Kenneth A. Berlin J.D. (Age 58)
Pres & CEO
Comp: $625.4k
Mr. Igor Gitelman CPA (Age 46)
CPA, M.B.A., MBA, Chief Accounting Officer, Interim CFO & VP of Fin.
Comp: $297.87k
Dr. Andres A. Gutierrez M.D. (Age 61)
Ph.D., Exec. VP & Chief Medical Officer
Comp: $472.03k

Key Competitors

View All Competitors

ADXS Stock - Frequently Asked Questions

How have ADXS shares performed in 2022?: Advaxis' stock was trading at $3.86 on January 1st, 2022. Since then, ADXS stock has decreased by 12.2% and is now trading at $3.39.
View the best growth stocks for 2022 here.
What other stocks do shareholders of Advaxis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), VistaGen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

What is Advaxis' stock symbol?: Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How do I buy shares of Advaxis?: Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Advaxis' stock price today?: One share of ADXS stock can currently be purchased for approximately $3.39.
How much money does Advaxis make?: Advaxis (NASDAQ:ADXS) has a market capitalization of $6.17 million and generates $3.24 million in revenue each year. The company earns $-17,860,000.00 in net income (profit) each year or ($6.70) on an earnings per share basis.
How can I contact Advaxis?: Advaxis' mailing address is 9 DEER PARK DRIVE SUITE K-1, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.advaxis.com. The company can be reached via phone at 609 452 9813, via email at tim@lifesciadvisors.com, or via fax at 609-452-9818.

This page (NASDAQ:ADXS) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources